New melphalan combo shows promise in Half-Matched transplants for blood cancer patients
NCT ID NCT03159702
First seen Feb 01, 2026 · Last updated Jun 12, 2026 · Updated 24 times
Summary
This study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approach is safe and helps patients live longer without their cancer getting worse. Results showed the treatment was generally safe, with serious side effects monitored, and one-year progression-free survival was evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.